Orphan, But Not Rare: Pipeline Is Full And Approvals Are Up
If current trends persist, in 2006 FDA could surpass the number of orphan status designations granted in the past two years
You may also be interested in...
FDA will amend its orphan drug regulations to specify the requirements for a disease subset to qualify as a rare disease for the purpose of orphan designations
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011